Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy
Heart failure (HF) with preserved left ventricular ejection fraction is a common disease with a poor prognosis and rising prevalence in the community. The current paradigm of treatment includes symptomatic therapy, such as diuretics, and risk factor control and treatment of comorbidities. According...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2022-07-01
|
| Series: | Cardiac Failure Review |
| Online Access: | https://www.cfrjournal.com/articleindex/cfr.2022.04 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849220257899610112 |
|---|---|
| author | Mauro Gori Emilia D’Elia Edoardo Sciatti Michele Senni |
| author_facet | Mauro Gori Emilia D’Elia Edoardo Sciatti Michele Senni |
| author_sort | Mauro Gori |
| collection | DOAJ |
| description | Heart failure (HF) with preserved left ventricular ejection fraction is a common disease with a poor prognosis and rising prevalence in the community. The current paradigm of treatment includes symptomatic therapy, such as diuretics, and risk factor control and treatment of comorbidities. According to European guidelines, there is no effective therapy for patients with HF with left ventricular ejection fraction (LVEF) ≥50%, while drugs normally used in HF with reduced LVEF might also be effective for patients with mildly reduced LVEF (40–50%), with a IIB class of recommendation. The recently published EMPEROR-Preserved trial has challenged current guidelines, demonstrating improved outcomes in patients with HF and LVEF >40% with the sodium–glucose cotransporter 2 inhibitor (SGLT2I) empagliflozin, compared with placebo. This result was consistent in patients with and without diabetes as well as in those with LVEF below and above 50%. The authors describe the rationale for this therapy, presenting the main results of the EMPEROR-Preserved trial, and provide some recommendations for the everyday clinical management of HF with preserved left ventricular ejection with an SGLT2I. |
| format | Article |
| id | doaj-art-3733938e4b7b43128f22d973d83e4c4b |
| institution | Kabale University |
| issn | 2057-7540 2057-7559 |
| language | English |
| publishDate | 2022-07-01 |
| publisher | Radcliffe Medical Media |
| record_format | Article |
| series | Cardiac Failure Review |
| spelling | doaj-art-3733938e4b7b43128f22d973d83e4c4b2024-12-14T16:03:46ZengRadcliffe Medical MediaCardiac Failure Review2057-75402057-75592022-07-01810.15420/cfr.2022.04Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful TherapyMauro Gori0Emilia D’Elia1Edoardo Sciatti2Michele Senni3Cardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, ItalyCardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, ItalyCardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, ItalyCardiovascular Department, Papa Giovanni XXIII Hospital, Bergamo, ItalyHeart failure (HF) with preserved left ventricular ejection fraction is a common disease with a poor prognosis and rising prevalence in the community. The current paradigm of treatment includes symptomatic therapy, such as diuretics, and risk factor control and treatment of comorbidities. According to European guidelines, there is no effective therapy for patients with HF with left ventricular ejection fraction (LVEF) ≥50%, while drugs normally used in HF with reduced LVEF might also be effective for patients with mildly reduced LVEF (40–50%), with a IIB class of recommendation. The recently published EMPEROR-Preserved trial has challenged current guidelines, demonstrating improved outcomes in patients with HF and LVEF >40% with the sodium–glucose cotransporter 2 inhibitor (SGLT2I) empagliflozin, compared with placebo. This result was consistent in patients with and without diabetes as well as in those with LVEF below and above 50%. The authors describe the rationale for this therapy, presenting the main results of the EMPEROR-Preserved trial, and provide some recommendations for the everyday clinical management of HF with preserved left ventricular ejection with an SGLT2I.https://www.cfrjournal.com/articleindex/cfr.2022.04 |
| spellingShingle | Mauro Gori Emilia D’Elia Edoardo Sciatti Michele Senni Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy Cardiac Failure Review |
| title | Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy |
| title_full | Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy |
| title_fullStr | Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy |
| title_full_unstemmed | Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy |
| title_short | Sodium–Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction: Rationale for and Practical Use of a Successful Therapy |
| title_sort | sodium glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction rationale for and practical use of a successful therapy |
| url | https://www.cfrjournal.com/articleindex/cfr.2022.04 |
| work_keys_str_mv | AT maurogori sodiumglucosecotransporter2inhibitorsinheartfailurewithpreservedejectionfractionrationaleforandpracticaluseofasuccessfultherapy AT emiliadelia sodiumglucosecotransporter2inhibitorsinheartfailurewithpreservedejectionfractionrationaleforandpracticaluseofasuccessfultherapy AT edoardosciatti sodiumglucosecotransporter2inhibitorsinheartfailurewithpreservedejectionfractionrationaleforandpracticaluseofasuccessfultherapy AT michelesenni sodiumglucosecotransporter2inhibitorsinheartfailurewithpreservedejectionfractionrationaleforandpracticaluseofasuccessfultherapy |